Parkinson's pharmacology Flashcards
Part of the basal ganglia where dopamine is synthesized
substantia nigra
A form of secondary parkinson’s disease that is caused by a viral infection
postencephalitic parkinsonism
DA receptors that are GPCRs that are generally excitatory
D1type (D1 and D5)
The most effective treatment of parkinson’s disease
levodopa
MOA of carbidopa
peripheral dopa decarboxylase inhibitor
MOA of entacopone
inhibits COMT in periphery
MOA of tolcapone
Inhibits COMT in periphery and CNS
Major risk associated with tolcapone
hepatic failure
Ergot D2-dopamine receptor agonist and partial D1 antagonist
Bromocriptine
MAO-B inhibitor that is not metabolized to amphetamine
resagiline
2 non-ergot D2 and D3 receptor agonists
Pramiprexole
Ropinirole
A dopamine receptor antagonist that is a SQ injection that is indicated for the acute, intermittent treatment of hypomobility, “off” episodes in advanced PD
apomorphine (Apokyn)
Anti-emetic therapy commonly used with apomorphine
trimethobenzamide
Anti-viral agent that can also be used in PD because it increases DA release and blocks NMDA receptors
amantadine
MAO-B inhibitor that has an amphetamine metabolite
selegiline